BIO - Bio-Rad Laboratories Inc Stock Price, Fair Value and News

293.85USD-1.88 (-0.64%)Market Closed

Market Summary

USD293.85-1.88

Market Closed

-0.64%

BIO Alerts

Big jump in Earnings (Y/Y)

BIO Stock Price

View Fullscreen

BIO RSI Chart

BIO Valuation

Market Cap

8.4B

Price/Earnings (Trailing)

-26.02

Price/Sales (Trailing)

3.22

EV/EBITDA

-23.21

Price/Free Cashflow

45.24

BIO Price/Sales (Trailing)

BIO Profitability

EBT Margin

-17.04%

Return on Equity

-3.56%

Return on Assets

-2.56%

Free Cashflow Yield

2.21%

BIO Fundamentals

BIO Revenue

Revenue (TTM)

2.6B

Rev. Growth (Yr)

-9.75%

Rev. Growth (Qtr)

-10.33%

BIO Earnings

Earnings (TTM)

-322.4M

Earnings Growth (Yr)

456.38%

Earnings Growth (Qtr)

9.78%

Breaking Down BIO Revenue

Last 7 days

4.3%

Last 30 days

1.1%

Last 90 days

-13.6%

Trailing 12 Months

-22.7%

How does BIO drawdown profile look like?

BIO Financial Health

Current Ratio

6.57

Debt/Equity

0.13

Debt/Cashflow

0.29

BIO Investor Care

Buy Backs (1Y)

3.64%

Diluted EPS (TTM)

-10.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.6B	0	0	0
2023	2.8B	2.8B	2.7B	2.7B
2022	2.9B	2.9B	2.8B	2.8B
2021	2.7B	2.9B	3.0B	2.9B
2020	2.3B	2.3B	2.4B	2.5B
2019	2.3B	2.3B	2.3B	2.3B
2018	2.2B	2.3B	2.3B	2.3B
2017	2.1B	2.1B	2.1B	2.2B
2016	2.0B	2.0B	2.1B	2.1B
2015	2.1B	2.1B	2.0B	2.0B
2014	2.1B	2.2B	2.2B	2.2B
2013	2.1B	2.1B	2.1B	2.1B
2012	2.1B	2.1B	2.0B	2.1B
2011	2.0B	2.0B	2.1B	2.1B
2010	1.8B	1.9B	1.9B	1.9B
2009	0	1.8B	1.8B	1.8B
2008	0	0	0	1.8B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Which funds bought or sold BIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Wahed Invest LLC	added	14.00	24,990	138,002	0.03%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	0.41	786,804	11,205,500	0.01%
May 16, 2024	Tidal Investments LLC	added	11.18	202,377	1,262,420	0.02%
May 16, 2024	LBP AM SA	sold off	-100	-10,699,000	-	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-80.51	-4,547,620	1,199,820	-%
May 16, 2024	COMERICA BANK	reduced	-5.03	217,378	12,815,900	0.06%
May 16, 2024	Global Financial Private Client, LLC	unchanged	-	226	4,746	-%
May 15, 2024	EARNEST PARTNERS LLC	added	30.81	50,990,100	178,091,000	0.81%
May 15, 2024	JANUS HENDERSON GROUP PLC	added	0.11	62,648	952,186	-%
May 15, 2024	Southpoint Capital Advisors LP	new	-	34,587,000	34,587,000	0.68%

Are Funds Buying or Selling BIO?

Are funds buying BIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BIO

No. of Funds

BIO Alerts

Big jump in Earnings (Y/Y)

Unveiling Bio-Rad Laboratories Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	vanguard group inc	10.36%	2,427,137	SC 13G/A
Feb 13, 2024	vanguard group inc	9.93%	2,389,889	SC 13G/A
Jan 29, 2024	blackrock inc.	6.1%	1,466,226	SC 13G/A
Feb 09, 2023	vanguard group inc	9.66%	2,391,436	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 01, 2023	blackrock inc.	6.4%	1,582,313	SC 13G/A
Apr 11, 2022	schwartz alice n	89.7%	4,555,452	SC 13D/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Feb 09, 2022	vanguard group inc	9.21%	2,287,465	SC 13G/A
Feb 01, 2022	blackrock inc.	7.1%	1,768,081	SC 13G/A

Recent SEC filings of Bio-Rad Laboratories Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	SD	SD
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	3	Insider Trading
May 08, 2024	S-8	Employee Benefits Plan
May 07, 2024	8-K	Current Report
May 01, 2024	4	Insider Trading
Apr 30, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	3	Insider Trading

Peers (Alternatives to Bio-Rad Laboratories Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

Bio-Rad Laboratories Inc News

Latest updates

Bio-Rad Laboratories Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-10.3%	611	681	632	681	677	730	681	691	700	733	747	716	727	790	647	537	572	625	561	573	554
Gross Profit	-11.0%	326	366	336	363	362	397	373	395	403	400	437	401	401	460	367	293	317	330	307	308	312
S&GA Expenses	3.7%	215	207	201	208	226	212	211	208	197	222	216	213	226	218	198	189	194	214	202	201	208
R&D Expenses	3.9%	66.00	64.00	44.00	65.00	75.00	66.00	67.00	64.00	60.00	59.00	64.00	63.00	74.00	57.00	60.00	52.00	49.00	57.00	48.00	50.00	48.00
EBITDA Margin	49.5%	-0.15*	-0.30*	0.00*	-0.12*	-0.02*	-1.61*	-2.73*	-0.85*	-0.02*	1.91*	2.93*	1.87*	2.03*	2.00*	1.97*	1.17*	0.94*	1.05*	0.30*	0.60*	0.41*
Interest Expenses	-0.7%	12.00	12.00	12.00	12.00	12.00	12.00	12.00	11.00	4.00	0.00	0.00	0.00	0.00	5.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00
Income Taxes	36.2%	107	79.00	31.00	-338	16.00	264	-44.51	-295	-1,000	-461	1,094	243	320	242	370	280	213	146	-76.40	171	262
Earnings Before Taxes	14.6%	491	428	137	-1,500	85.00	1,091	-207	-1,220	-4,368	-2,027	5,022	1,157	1,297	1,089	1,685	1,246	899	699	-335	770	1,127
EBT Margin	46.5%	-0.17*	-0.32*	-0.07*	-0.19*	-0.09*	-1.68*	-2.79*	-0.90*	-0.07*	1.86*	2.87*	1.82*	1.97*	1.93*	1.90*	1.09*	0.87*	0.98*	0.23*	0.53*	0.34*
Net Income	9.8%	384	350	106	-1,162	69.00	828	-162	-925	-3,367	-1,572	3,930	917	980	839	1,315	966	686	554	-258	599	865
Net Income Margin	48.1%	-0.12*	-0.24*	-0.06*	-0.15*	-0.07*	-1.29*	-2.15*	-0.67*	-0.03*	1.46*	2.24*	1.41*	1.52*	1.50*	1.48*	0.85*	0.68*	0.76*	0.16*	0.40*	0.25*
Free Cashflow	-23.6%	30.00	39.00	54.00	63.00	62.00	45.00	-16.58	36.00	17.00	115	196	131	94.00	246	116	74.00	41.00	138	69.00	133	19.00

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	2.5%	12,610	12,299	11,896	11,978	13,667	13,502	12,058	12,682	14,374	17,799	19,953	15,118	13,933	12,973	12,021	10,097	8,684	8,009	7,177	7,647	6,863
Current Assets	0.4%	3,061	3,048	3,147	3,139	3,277	3,158	3,140	3,250	3,303	1,990	2,466	2,289	2,175	2,140	2,324	2,133	2,083	2,180	2,048	2,088	2,032
Cash Equivalents	7.4%	434	404	458	390	464	434	518	597	802	471	860	733	673	667	840	608	604	663	561	581	456
Inventory	0.4%	783	781	776	777	753	719	686	657	605	572	589	599	605	622	640	628	557	554	588	590	590
Net PPE	-100.0%	-	529	-	-	-	499	-	-	-	512	-	-	-	491	-	-	486	499	496	499	503
Goodwill	-0.2%	413	414	407	412	408	406	400	347	346	347	292	292	292	292	292	292	264	264	264	235	231
Liabilities	0.0%	3,559	3,558	3,480	3,531	3,904	3,886	3,605	3,760	4,191	4,114	4,621	3,523	3,324	3,093	3,196	2,744	2,391	2,254	2,046	2,160	1,999
Current Liabilities	-10.8%	466	523	558	582	590	569	571	614	648	681	650	587	610	632	987	927	869	905	434	446	444
Long Term Debt	0.0%	1,199	1,199	1,199	1,198	1,198	1,198	1,197	1,197	1,197	11.00	11.00	11.00	11.00	12.00	12.00	12.00	12.00	14.00	438	438	438
LT Debt, Non Current	-	-	-	1,199	1,198	1,198	1,198	1,197	1,197	1,197	11.00	11.00	11.00	11.00	12.00	12.00	12.00	12.00	14.00	438	438	438
Shareholder's Equity	3.5%	9,051	8,741	8,416	8,447	9,764	9,615	8,477	8,945	10,203	13,685	15,332	11,595	10,609	9,890	8,825	7,353	6,293	5,757	5,131	5,487	4,864
Retained Earnings	4.1%	9,645	9,261	8,911	8,805	9,967	9,898	9,047	9,210	10,138	13,525	15,081	11,159	10,245	9,268	8,429	7,123	6,157	5,471	4,917	5,185	4,586
Additional Paid-In Capital	3.0%	463	449	439	474	463	447	431	472	459	442	421	460	445	429	412	429	424	410	396	411	403
Accumulated Depreciation	-	-	-	-	-	-	1,009	-	-	-	1,002	-	-	-	961	-	-	876	883	851	850	828
Shares Outstanding	-2.4%	29.00	29.00	29.00	29.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00
Float	-	-	-	-	7,746	-	-	-	68.00	-	-	-	13,641	-	-	-	9,502	-	-	-	6,613	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-13.8%	69,792	81,000	97,715	98,066	98,119	79,610	10,990	53,306	50,494	170,900	230,366	154,624	113,610	294,400	135,700	92,092	62,808	159,802	99,750	155,445	42,900
Share Based Compensation	-	15,300	-	-	-	16,600	-	-	-	-	-	-	-	-	-	10,800	-	-	-	9,100	-	-
Cashflow From Investing	-159.7%	-43,093	72,197	-9,500	27,984	-70,473	-58,552	-88,419	-144,481	-916,141	-567,427	-81,350	-100,277	-48,327	-59,753	90,854	-88,573	-12,422	-61,196	-109,909	-15,071	-22,713
Cashflow From Financing	100.0%	21.00	-200,620	-26,598	-202,738	4,309	-86,619	-8,772	-121,326	1,190,293	4,635	-15,582	2,865	-47,347	-421,884	439	-2,979	-98,617	-4,783	-4,491	-15,645	2,161
Buy Backs	-97.6%	4,749	200,000	21,321	207,407	-	90,679	-	125,000	-	-	-	-	49,998	-	-1.00	-	100,005	8,000	4,999	15,001	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BIO Income Statement

2024-03-31

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net sales	$ 610,820	$ 676,844
Cost of goods sold	284,854	314,427
Gross profit	325,966	362,417
Selling, general and administrative expense	214,883	225,553
Research and Development Expense	66,375	74,951
Segment profit (loss)	44,708	61,913
Interest expense	12,277	12,337
Foreign exchange (gains) losses, net	(1,954)	(2,347)
Marketable Securities, Unrealized (Gain) Loss	(422,177)	17,525
Other Nonoperating Income (Expense)	34,516	50,431
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	491,078	84,829
(Provision) benefit for income taxes	(107,162)	(15,867)
Net income attributable to Bio-Rad	$ 383,916	$ 68,962
Basic earnings per share:
Net income per share basic attributable to Bio-Rad	$ 13.46	$ 2.33
Weighted average common shares - basic	28,518	29,596
Diluted earnings per share:
Net income per share diluted attributable to Bio-Rad	$ 13.45	$ 2.32
Weighted average common shares - diluted	28,537	29,747

BIO Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
ASSETS:
Cash and cash equivalents	$ 433,280	$ 403,815
Short-term investments	1,212,394	1,203,327
Restricted investments	5,560	5,560
Accounts receivable, net	444,809	489,017
Inventory	783,369	780,517
Prepaid expenses	142,742	140,040
Other current assets	38,782	26,054
Total current assets	3,060,936	3,048,330
Property, plant and equipment, net	522,364	529,007
Operating lease right-of-use assets	188,918	194,730
Goodwill, net	412,817	413,569
Purchased intangibles, net	313,602	320,514
Other investments	8,018,383	7,698,070
Other assets	92,873	94,850
Assets	12,609,893	12,299,070
LIABILITIES AND STOCKHOLDERS' EQUITY:
Accounts payable	102,750	144,625
Accrued payroll and employee benefits	146,491	139,929
Current maturities of long-term debt and notes payable	487	486
Income and other taxes payable	33,961	35,759
Current operating lease liabilities	40,038	40,379
Other current liabilities	142,427	161,621
Total current liabilities	466,154	522,799
Long-term debt, net of current maturities	1,199,381	1,199,052
Deferred income taxes	1,540,992	1,475,495
Operating lease liabilities	159,814	165,478
Other long-term liabilities	192,418	195,113
Total liabilities	3,558,759	3,557,937
Stockholders' equity:
Additional paid-in capital	462,627	449,075
Retained earnings	9,644,545	9,260,629
Accumulated other comprehensive loss	(425,971)	(336,038)
Total stockholders' equity	9,051,134	8,741,133
Total liabilities and stockholders' equity	12,609,893	12,299,070
Common Class A [Member]
Stockholders' equity:
Common stock	2	2
Common Class B [Member]
Stockholders' equity:
Common stock	1	1
Treasury Stock, Common
Stockholders' equity:
Treasury stock	$ (630,070)	$ (632,536)

About Bio-Rad Laboratories Inc

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

CEO	Mr. Norman D. Schwartz
WEBSITE	bio-rad.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	8200

Bio-Rad Laboratories Inc Frequently Asked Questions

What is the ticker symbol for Bio-Rad Laboratories Inc? What does BIO stand for in stocks?

BIO is the stock ticker symbol of Bio-Rad Laboratories Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bio-Rad Laboratories Inc (BIO)?

As of Fri May 17 2024, market cap of Bio-Rad Laboratories Inc is 8.39 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIO stock?

You can check BIO's fair value in chart for subscribers.

What is the fair value of BIO stock?

You can check BIO's fair value in chart for subscribers. The fair value of Bio-Rad Laboratories Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bio-Rad Laboratories Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bio-Rad Laboratories Inc a good stock to buy?

The fair value guage provides a quick view whether BIO is over valued or under valued. Whether Bio-Rad Laboratories Inc is cheap or expensive depends on the assumptions which impact Bio-Rad Laboratories Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIO.

What is Bio-Rad Laboratories Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, BIO's PE ratio (Price to Earnings) is -26.02 and Price to Sales (PS) ratio is 3.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bio-Rad Laboratories Inc's stock?

In the past 10 years, Bio-Rad Laboratories Inc has provided 0.093 (multiply by 100 for percentage) rate of return.